About usOur teamOur pipelineNewsContact us

Abstracts & publications

February 2021
Radiotheranostic targeting of fPSA
Read moreRead more
December 2020
Inter- and intraobserver agreement of the quantitative assessment of [99mTc]-labelled anti-programmed death-ligand 1 (PD-L1) SPECT/CT in non-small cell lung cancer
Read moreRead more
December 2020
Why next generation radiopharmaceuticals will play a key role in the quest for precision medicine
Read moreRead more
September 2019
Open Access Early Phase I Study of a 99mTc-Labeled Anti–Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non–Small Cell Lung Cancer
Read moreRead more
January 2016
Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle
Read moreRead more
July 2014
Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer
Read moreRead more
June 2008
99mTc-Labeled Nanobodies: A New Type of Targeted Probes for Imaging Antigen Expression
Read moreRead more

Sign up to our mailing list.

Receive all the latest news from Radiopharm Theranostics.